vs
Side-by-side financial comparison of AMERICAN FINANCIAL GROUP INC (AFG) and Hologic (HOLX). Click either name above to swap in a different company.
AMERICAN FINANCIAL GROUP INC is the larger business by last-quarter revenue ($2.1B vs $1.0B, roughly 2.0× Hologic). Hologic runs the higher net margin — 17.1% vs 14.5%, a 2.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -4.0%). Over the past eight quarters, AMERICAN FINANCIAL GROUP INC's revenue compounded faster (4.0% CAGR vs 1.5%).
The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
AFG vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $1.0B |
| Net Profit | $299.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 18.4% | 22.6% |
| Net Margin | 14.5% | 17.1% |
| Revenue YoY | -4.0% | 2.5% |
| Net Profit YoY | 17.3% | -10.9% |
| EPS (diluted) | $3.59 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | $1.0B | ||
| Q3 25 | $2.3B | $1.0B | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.9B | $1.0B | ||
| Q4 24 | $2.1B | $1.0B | ||
| Q3 24 | $2.4B | $988.0M | ||
| Q2 24 | $1.9B | $1.0B | ||
| Q1 24 | $1.9B | $1.0B |
| Q4 25 | $299.0M | $179.1M | ||
| Q3 25 | $215.0M | $187.2M | ||
| Q2 25 | $174.0M | $194.9M | ||
| Q1 25 | $154.0M | $-17.4M | ||
| Q4 24 | $255.0M | $201.0M | ||
| Q3 24 | $181.0M | $178.6M | ||
| Q2 24 | $209.0M | $194.5M | ||
| Q1 24 | $242.0M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | 18.4% | 22.6% | ||
| Q3 25 | 11.5% | 22.6% | ||
| Q2 25 | 11.9% | 24.9% | ||
| Q1 25 | 10.6% | -0.7% | ||
| Q4 24 | 14.9% | 22.5% | ||
| Q3 24 | 9.7% | 23.3% | ||
| Q2 24 | 14.3% | 24.1% | ||
| Q1 24 | 15.9% | 20.7% |
| Q4 25 | 14.5% | 17.1% | ||
| Q3 25 | 9.2% | 17.8% | ||
| Q2 25 | 9.0% | 19.0% | ||
| Q1 25 | 8.3% | -1.7% | ||
| Q4 24 | 11.9% | 19.7% | ||
| Q3 24 | 7.6% | 18.1% | ||
| Q2 24 | 11.0% | 19.2% | ||
| Q1 24 | 12.7% | 16.7% |
| Q4 25 | $3.59 | $0.79 | ||
| Q3 25 | $2.58 | $0.84 | ||
| Q2 25 | $2.07 | $0.86 | ||
| Q1 25 | $1.84 | $-0.08 | ||
| Q4 24 | $3.03 | $0.87 | ||
| Q3 24 | $2.16 | $0.75 | ||
| Q2 24 | $2.49 | $0.82 | ||
| Q1 24 | $2.89 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $2.4B |
| Total DebtLower is stronger | $1.8B | $2.5B |
| Stockholders' EquityBook value | $4.8B | $5.2B |
| Total Assets | $32.6B | $9.2B |
| Debt / EquityLower = less leverage | 0.38× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $2.4B | ||
| Q3 25 | $1.8B | $2.2B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $1.1B | $2.4B | ||
| Q1 24 | $1.1B | $2.2B |
| Q4 25 | $1.8B | $2.5B | ||
| Q3 25 | $1.8B | $2.5B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.5B | $2.5B | ||
| Q4 24 | $1.5B | $2.5B | ||
| Q3 24 | $1.5B | $2.5B | ||
| Q2 24 | $1.5B | $2.5B | ||
| Q1 24 | $1.5B | $2.6B |
| Q4 25 | $4.8B | $5.2B | ||
| Q3 25 | $4.7B | $5.0B | ||
| Q2 25 | $4.5B | $4.8B | ||
| Q1 25 | $4.4B | $4.6B | ||
| Q4 24 | $4.5B | $4.8B | ||
| Q3 24 | $4.7B | $5.1B | ||
| Q2 24 | $4.4B | $5.0B | ||
| Q1 24 | $4.2B | $4.8B |
| Q4 25 | $32.6B | $9.2B | ||
| Q3 25 | $33.8B | $9.0B | ||
| Q2 25 | $30.7B | $8.8B | ||
| Q1 25 | $30.3B | $8.5B | ||
| Q4 24 | $30.8B | $8.7B | ||
| Q3 24 | $32.6B | $9.2B | ||
| Q2 24 | $29.9B | $8.9B | ||
| Q1 24 | $30.0B | $8.7B |
| Q4 25 | 0.38× | 0.48× | ||
| Q3 25 | 0.38× | 0.50× | ||
| Q2 25 | 0.33× | 0.52× | ||
| Q1 25 | 0.34× | 0.55× | ||
| Q4 24 | 0.33× | 0.53× | ||
| Q3 24 | 0.31× | 0.49× | ||
| Q2 24 | 0.34× | 0.51× | ||
| Q1 24 | 0.35× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $784.0M | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 2.62× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $784.0M | $229.9M | ||
| Q3 25 | $216.0M | $355.1M | ||
| Q2 25 | $191.0M | $343.3M | ||
| Q1 25 | $342.0M | $169.4M | ||
| Q4 24 | $674.0M | $189.3M | ||
| Q3 24 | $459.0M | $367.0M | ||
| Q2 24 | $-88.0M | $405.8M | ||
| Q1 24 | $107.0M | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | — | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | 2.62× | 1.28× | ||
| Q3 25 | 1.00× | 1.90× | ||
| Q2 25 | 1.10× | 1.76× | ||
| Q1 25 | 2.22× | — | ||
| Q4 24 | 2.64× | 0.94× | ||
| Q3 24 | 2.54× | 2.05× | ||
| Q2 24 | -0.42× | 2.09× | ||
| Q1 24 | 0.44× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AFG
| Property And Casualty Insurance | $2.0B | 96% |
| Other | $83.0M | 4% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
